More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments Vrije Universiteit Brussel
Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the ...